Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Reuters
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emir…
-
General15 hours agoWA Police investigate death of baby in Baldivis in Perth’s southern suburbs
-
Noosa News12 hours agoFatal e-bike crash, Mountain Creek (Sunshine Coast)
-
Noosa News21 hours agoBrisbane bus driver found guilty over CBD crash that killed Tia Cameron
-
Noosa News19 hours agoBus driver found guilty over death of 18yo Tia Cameron